Norway Antiviral Drugs Market Size & Outlook, 2022-2030
Norway antiviral drugs market, 2018-2030 (US$M)
Related Markets
Norway antiviral drugs market highlights
- The Norway antiviral drugs market generated a revenue of USD 988.3 million in 2022 and is expected to reach USD 883.4 million by 2030.
- The Norway market is expected to grow at a CAGR of -1.4% from 2023 to 2030.
- In terms of segment, hiv was the largest revenue generating application in 2022.
- Herpes is the most lucrative application segment registering the fastest growth during the forecast period.
Antiviral drugs market data book summary
| Market revenue in 2022 | USD 988.3 million |
| Market revenue in 2030 | USD 883.4 million |
| Growth rate | -1.4% (CAGR from 2022 to 2030) |
| Largest segment | Hiv |
| Fastest growing segment | Herpes |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | HIV, Hepatitis, Herpes, Influenza |
| Key market players worldwide | Roche Holding AG, GSK PLC ADR, AbbVie Inc, Merck & Co Inc, Johnson & Johnson, Bristol-Myers Squibb Co, Dr Reddy's Laboratories Ltd ADR, Aurobindo Pharma |
Other key industry trends
- In terms of revenue, Norway accounted for 1.4% of the global antiviral drugs market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antiviral drugs market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 5,153.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antiviral Drugs Market Scope
Antiviral Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway antiviral drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antiviral drugs market will help companies and investors design strategic landscapes.
Hiv was the largest segment with a revenue share of 34.44% in 2022. Horizon Databook has segmented the Norway antiviral drugs market based on hiv, hepatitis, herpes, influenza covering the revenue growth of each sub-segment from 2018 to 2030.
Similar to other European countries, Norway witnesses a high demand for antiviral drugs due to the country's high prevalence of viral diseases. Moreover, Norway is the flu hotspot in the European region owing to higher infection rates of the disease.
As per estimates, 50% to 80% of the population in the country suffers from primary HSV-1 infection, which makes it important for key players to formulate and maintain product availability in the country.
Moreover, key players are focusing on developing newer formulations to meet the increasing demand for new-generation products. Some of the leading antiviral drug players in the market are GSK plc, Viatris, and AstraZeneca.
Reasons to subscribe to Norway antiviral drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway antiviral drugs market databook
-
Our clientele includes a mix of antiviral drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway antiviral drugs market , including forecasts for subscribers. This country databook contains high-level insights into Norway antiviral drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway antiviral drugs market size, by application, 2018-2030 (US$M)
Norway Antiviral Drugs Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
